The sales of Dexid for diabetic polyneuropathy, Legalon for liver disease, and Entecavir for chronic hepatitis B are boosted with double-digit growth in the first five months of the year.
Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) booked a double-digit growth rate in cumulative prescription rate for Dexid (an incrementally modified drug for polyneuropathy), Legalon (milk thistle extract for liver disease) and Entecavir (a treatment for chronic hepatitis B) in the first five months of 2019. (source: UBIST data)
Dexid is an incrementally modified new drug independently developed by Bukwang. Despite increased generic competition, Dexid is still dominating the market with 10.7% growth rate. In fact, the presence of generic drugs has contributed in increasing patient’s awareness to the condition, resulting in an increased market size that benefits both original and generic companies.
Legalon capsule, an original product of milk thistle extract, maintains its top tier rank in hepatoprotective agent market. The first five months saw the prescription value up reaching 6.1 billion KRW with 12.8% growth from the same periods a year earlier. The current performance of Legalon is expected to continuously grow during the second half of the year.
Bukwang’s Entecavir, a generic product launched five years ago, booked a 22.9% growth in prescription rate compared to the prior corresponding period. Bukwang maintains its strong presence in gastroenterology, thanks to its hepatitis B portfolio and its extensive knowledge in the field.
According to Bukwang’s official, “significant growth in prescription rate of different product portfolios is mainly contributed from General Hospitals. This achievement was also made possible by the hardwork and dedication of our well-trained sales representatives”.
“With recent introduction of Selbex and Meditoxin, pivotal clinical trial currently ongoing for Lurasidone--an antipsychotic to treat schizophrenia, and also ongoing licensing discussion with multiple companies, Bukwang is very confident to see continuous growth of the company going forward.”